Welcome to our dedicated page for Emmaus Life Scie SEC filings (Ticker: EMMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sickle cell disease therapies often come with complex clinical data, and Emmaus Life Sciences’ SEC filings are no exception. Revenue tied to Endari®, royalty agreements, and trial milestones can span hundreds of pages—making it hard to spot what really moves EMMA’s share price.
Stock Titan solves that problem. Our AI reads every Emmaus Life Sciences annual report 10-K simplified, quarterly earnings report 10-Q filing, and 8-K material events explained in plain English. Need Emmaus Life Sciences insider trading Form 4 transactions? We stream them in real time so you’ll know the moment an executive buys or sells.
Here’s what you can uncover in seconds:
- Pipeline & FDA Updates (8-K): Track trial readouts or approval notices without wading through legal language.
- Cash-flow Drivers (10-Q): Our AI tags Endari segment sales and R&D spend for fast comparison.
- Governance Details (DEF 14A): Read the Emmaus Life Sciences proxy statement executive compensation with key pay metrics already highlighted.
- Insider Signals (Form 4): Follow Emmaus Life Sciences Form 4 insider transactions real-time and spot buying patterns ahead of catalysts.
Whether you’re understanding Emmaus Life Sciences SEC documents with AI for the first time or need deeper Emmaus Life Sciences earnings report filing analysis, Stock Titan turns dense disclosures into practical insights—updated the moment EDGAR posts them.
Emmaus Life Sciences filed its Q3 2025 10-Q, highlighting a sharp revenue decline and liquidity strain alongside a going concern warning. Q3 revenue was $3.38 million versus $5.48 million a year ago, and the company posted a net loss of $2.08 million versus net income of $1.83 million in Q3 2024. Operating profit of $0.70 million was outweighed by other expense of $2.19 million, driven mainly by interest expense of $1.93 million.
For the nine months, revenue was $8.60 million versus $13.36 million. Cash was $0.29 million with current liabilities of $64.17 million, and total liabilities of $80.24 million against assets of $20.76 million, resulting in a stockholders’ deficit of $59.49 million. Management states there is substantial doubt about continuing as a going concern without restructuring debt and raising additional financing. The company also recorded a $0.53 million realized loss year‑to‑date on its Telcon convertible bond.
FAQ
What is the current stock price of Emmaus Life Scie (EMMA)?
What is the market cap of Emmaus Life Scie (EMMA)?
